Navigation Links
ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase
Date:4/23/2008

TUCSON, Ariz., April 23 /PRNewswire-FirstCall/ -- ImaRx Therapeutics, Inc. (Nasdaq: IMRX) today announced that it has entered into an agreement with Abbott Laboratories pursuant to which it has satisfied its obligations under its $15 million non-recourse promissory note with Abbott issued in connection with its acquisition of urokinase. As a result, full title to the urokinase assets, including the remaining inventory of finished product, all regulatory and clinical documentation, validated cell lines, and intellectual property rights, now resides unencumbered with ImaRx.

Urokinase is a thrombolytic drug, formerly marketed under the brand name Abbokinase(R) and recently re-branded as Kinlytic(TM). Urokinase is FDA approved and marketed for the treatment of acute massive pulmonary embolism, or blood clots in the lungs.

As of March 31, 2008, the remaining balance due under the note net of funds that were held in escrow totaled approximately $10.8 million. Pursuant to the terms of the agreement, all of ImaRx's obligations under the $15 million non-recourse promissory note were fully satisfied in exchange for the payment of $5,177,609 in cash to Abbott and the satisfaction of certain payment obligations relating to the storage of certain cell banks and recombinant samples at a contract research organization.

Bradford A. Zakes, President and CEO of ImaRx Therapeutics, stated, "We are pleased to have reached agreement with Abbott Laboratories on the satisfaction of this debt obligation. This now ensures that we have complete ownership of the asset, which will enable us to continue to commercialize this product and to provide patients and their doctors access to this important therapeutic."

About ImaRx Therapeutics '/>"/>

SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. ImaRx Therapeutics Receives Notification from NASDAQ Regarding Non-Compliance with NASDAQs Minimum Bid Price Requirement
2. ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
3. ImaRx Reschedules Release of Corporate Updates and Fourth Quarter and Full Year 2007 Financial Results
4. ImaRx to Report Corporate Updates and 4Q07 Financial Results
5. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
6. Sirion Therapeutics Preclinical Studies: Two New Potential Advances in Treatment of Retinal Diseases to be Presented at ARVO
7. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
8. Cell Therapeutics, Inc. Announces Receipt of Letter From the NASDAQ Stock Market Regarding Non-Compliance With the Minimum Bid Price Requirement
9. BioSpace and IBC Life Sciences Announce Career Fair Alliance For Drug Discovery & Development of Innovative Therapeutics World Congress
10. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
11. CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)..., part of Life Technologies Corporation (NASDAQ:LI...h and discovery solutions, today announced that it... the SOLiD™ System, has been named the Life ...entist, a leading scientific publication focused o...ement of the first-ever Life Science Innovation of...
(Date:12/3/2008)...nd secondhand smoke, an estimated ten percent of p...f a developing baby to harmful cigarette byproduct...000 newborns each year and poses a significant hea...s kind, a team of researchers has completed a glob... better understand the fetal health risks from smo...
(Date:12/3/2008)...FirstCall/ -- GlaxoSmithKline,(LSE/NYSE: GSK ) ...ating to a,pending lawsuit in the previously anno...ding shares of common stock of Genelabs Technologi...n cash without interest and less any,required wit...completion of the tender offer that there not be,...
(Date:12/3/2008)...-- Cellectricon, a leading,provider of screening ...,signing of a collaborative agreement with The Aut...s of advanced automated systems for cell culture, ...pplications. Under the agreement,TAP will co-deve...ectricon,s,next generation high throughput ion ch...
Breaking Biology Technology: Applied Biosystems SOLiD System Named Life Science Innovation of the Year : The Scientist Magazine Cites the Technology's High Throughput, Lower Sequencing Cost, and Rapid Technology Innovation for Unlocking New Approaches to Clinical Research 2 Applied Biosystems SOLiD System Named Life Science Innovation of the Year : The Scientist Magazine Cites the Technology's High Throughput, Lower Sequencing Cost, and Rapid Technology Innovation for Unlocking New Approaches to Clinical Research 3 Applied Biosystems SOLiD System Named Life Science Innovation of the Year : The Scientist Magazine Cites the Technology's High Throughput, Lower Sequencing Cost, and Rapid Technology Innovation for Unlocking New Approaches to Clinical Research 4 Applied Biosystems SOLiD System Named Life Science Innovation of the Year : The Scientist Magazine Cites the Technology's High Throughput, Lower Sequencing Cost, and Rapid Technology Innovation for Unlocking New Approaches to Clinical Research 5Cutting the cord to determine babies' health risk from toxic exposure 2Cutting the cord to determine babies' health risk from toxic exposure 3Cutting the cord to determine babies' health risk from toxic exposure 4GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc. 2GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc. 3Cellectricon Partners With The Automation Partnership - Bringing Next Generation Ion Channel Screening System to Market. 2Cellectricon Partners With The Automation Partnership - Bringing Next Generation Ion Channel Screening System to Market. 3
...ely following the progress of the Health Insuranc...electronic health records for the last eight month... dentist with a small healthcare business, I have ...all a "stakeholder" in this exciting and promising...re important than my job, I am a husband and fathe...
...- BellBrook Labs has been awarded two federal gran...opment of its enzyme screening product. , ,The bio... screening tools for the drug-therapy market, said...l Business Innovation Research (SBIR) awards. Hig...ct millions of biochemical, genetic, or pharmacolo...
...- An education research team at the University of...he MacArthur Foundation to study the impact of d...acy. , ,MacArthur,s total $50 million investment ...cts of the digital revolution and its educational ...actually trying to do, with this grant to us, is e...
...eek in Austin , Dallas , and Boston , getting a...art ups. (Yep, you guessed it, the search for DEMO...h of what I saw was quite impressive. It was also ...lley . , ,Where Silicon Valley is at the apex of ...dership in IT systems management. In Dallas, I fou...
Other Biology Technology:Careful with that electronic health record, Mr. Leavitt 2Careful with that electronic health record, Mr. Leavitt 3Careful with that electronic health record, Mr. Leavitt 4Grants worth $800,000 help BellBrook Labs develop products 2UW gets $3M to explore educational gaming 2UW gets $3M to explore educational gaming 3What makes Silicon Valley so different? 2What makes Silicon Valley so different? 3What makes Silicon Valley so different? 4
(Date:12/4/2008)...en want younger women, often touting their intelli...earch at Gothenburg University and Oxford Universi...en and women choose partners. , Research in the ...theories about how men and women choose their part... place more emphasis on attractive appearance, whe...
(Date:12/3/2008)...nes, deputy executive director of the Internationa...tlook 2008" Dec. 9 at Rice University,s Baker Inst...ch questions as: Is the world facing a supply crun...at type of post-Kyoto policy framework might stabi... and what impact might such a policy framework hav...
(Date:12/3/2008)...re. December 3, 2008. The first 5-year forest inve... is now available to the public: Oregon,s Forest R...d Analysis Report. , Here are some key findings ... 30 million acres; about half of Oregon,s total la...ng converted to other uses particularly near urban...
(Date:12/3/2008)...-- A Duke University study suggests that evolution... the dogs depend on an energy-efficient style of f...eir prey, cats seem to have evolved a profoundly i...e or bird in slow motion. , "It is usually assum...said Daniel Schmitt, a Duke associate professor of...
Breaking Biology News(10 mins):Myth about 'dirty old men' supported by science 2'World Energy Outlook' to be presented at Rice University Dec. 9 2Forest inventories in Oregon include more than trees 2Forest inventories in Oregon include more than trees 3Dogs chase efficiently, but cats skulk counterintuitively 2Some Iraq War Vets Suffer Breathing Problems 19978 1Some Iraq War Vets Suffer Breathing Problems 19978 2Some Iraq War Vets Suffer Breathing Problems 19978 3Emerging Capital Partners Invests 2447 3 Million in North African Personal Care Company 19973 1Emerging Capital Partners Invests 2447 3 Million in North African Personal Care Company 19973 2FDA Accepts Zingo 28TM 29 Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults 5547 1FDA Accepts Zingo 28TM 29 Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults 5547 2FDA Accepts Zingo 28TM 29 Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults 5547 3FDA Accepts Zingo 28TM 29 Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults 5547 4Low intensity case management cuts COPD related hospital visits in half 19966 1Low intensity case management cuts COPD related hospital visits in half 19966 2
...omparison of equipment that can analyze the expres...etic "fingerprint," suggests these different micro...t. , Published in the May 2005 issue of Nature Me... of information generated by these systems might a...systems are used by many different laboratories. ,...
...he University of Liverpool have discovered how the...f Europeans resistant to HIV. Scientists have know...etic mutation (known as CCR5-delta32) that prevent...system but have been unable to account for the hig... low levels in areas bordering the Mediterranean. ...
...of North Carolina at Chapel Hill is one of five cl...e National Institutes of Health to study why good ...ring the next seven years, the Drug-Induced Liver ...have suffered severe liver injury caused by prescr...al supplements, alternative medicines and herbals....
... microarray analyses result in many differentially...for the biological process of interest. In order t...publications from MEDLINE were identified in which... with specific keywords were co-mentioned. , MEDLI... keywords were generated and validated. PubMed IDs...
Other Biology News:Different microarray systems more alike than previously thought 2Different microarray systems more alike than previously thought 3First North American Encapsulated Islet Transplant without Long-term Immune Suppression into a Patient with Type 1 Diabetes 2UNC launches study of liver injury caused by drugs 2
MOUSE ANTI HUMAN MBP (67-74) Immunogen: Human myelin basic protein
MOUSE ANTI BOVINE TROPONIN I
Ready-to-use; 40mg/ml X-Gal and 32mg/ml IPTG
Normal donkey serum collected from healthy normal donkeys.
Biology Products: